BioCentury | Nov 1, 2012
Cover Story

Revving up glycolysis

...production of the oncogenic metabolite 2-hydroxyglutarate Dynamix Pharmaceuticals Ltd. has a small molecule PKM2 activator, DNX-3000...
BioCentury | Nov 1, 2012
Distillery Therapeutics

Indication: Cancer

...Pharmaceuticals Inc. has a preclinical-stage program targeting PKM2 in cancer. Dynamix Pharmaceuticals Ltd.'s PKM2 activator, DNX-3000...
BioCentury | Oct 25, 2012
Distillery Therapeutics

Indication: Cancer

...Pharmaceuticals Inc. has a discovery-stage program targeting PKM2 in cancer. Dynamix Pharmaceuticals Ltd.'s PKM2 activator, DNX-3000...
BioCentury | Oct 11, 2012
Distillery Therapeutics

Indication: Cancer

...Pharmaceuticals Inc. has a discovery-stage program targeting PKM2 in cancer. Dynamix Pharmaceuticals Ltd.'s PKM2 activator, DNX-3000...
BioCentury | Dec 1, 2011
Distillery Therapeutics

Indication: Cancer

...Agios Pharmaceuticals Inc. has a discovery-stage program targeting PKM2 in cancer. Dynamix Pharmaceuticals Ltd. has DNX-3000...
BioCentury | Nov 17, 2011
Distillery Therapeutics

Indication: Cancer

...Agios Pharmaceuticals Inc. has a discovery program targeting PKM2 to treat cancer. Dynamix Pharmaceuticals Ltd.'s DNX-3000...
Items per page:
1 - 6 of 6